Endocrinology and Metabolism (original) (raw)

Table 1 Prevalence of Hypercholesterolemia among Korean Adults ≥30 Years Old in 2015

aSerum total cholesterol ≥240 mg/dL or taking lipid-lowering medications; bAll over 30 years old.

Table 2 Trends in the Prevalence of Hypercholesterolemia, 2010 to 2015

Values are expressed as mean±standard error.

aSerum total cholesterol ≥240 mg/dL or taking lipid-lowering medications.

Table 3 Cholesterol Levels among Adults Aged 20 and over in the United States Based on the National Health and Nutrition Examination Survey for Selected Years (1988 to 1994 through 2011 to 2014)

aSerum total cholesterol ≥240 mg/dL or taking cholesterol-lowering medications; bSerum total cholesterol ≥240 mg/dL.

Table 4 Prevalence of Hypertriglyceridemia in Korean Adults ≥30 Years Old in 2015

aSerum triglyceride level ≥200 mg/dL; bAll over 30 years old.

Table 5 Trends in the Prevalence of Hypertriglyceridemia, 2010 to 2015

Values are expressed as mean±standard error.

aSerum triglyceride level ≥200 mg/dL.

Table 6 Management Status of Hypercholesterolemia in Participants of the Sixth Korean National Health and Nutrition Examination Survey (2013 to 2015)

Values are expressed as percentage.

aAwareness: proportion of the population diagnosed by a doctor; bAll over 30 years old; cTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; dRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; eRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.

Table 7 Management Status of Hypercholesterolemia during the Most Recent 10 Years

Values are expressed as mean±standard error.

KNHANES, Korean National Health and Nutrition Examination Survey.

aAwareness: proportion of the population diagnosed by a doctor; bTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; cRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; dRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.